1. Akebia Therapeutics, Inc. (AKBA) Stock Forum & Discussion
Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and ...
Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
2. AKBA Akebia Therapeutics Inc. - Stocktwits
Track Akebia Therapeutics Inc. (AKBA) Stock Price, Quote, latest community messages, chart, news and other stock related information.
Track Akebia Therapeutics Inc. (AKBA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
3. AKBA Conversations From StockTwits - StockNews
14 aug 2021 · The FDA assigned the application a standard review and a PDUFA target action date of March 29, 2022. Cash, cash equivalents and available-for- ...
$AKBAMarket Price - $2.56Average Hold - $3.40Accumulate - Sub $2.45 (raised from $2.30)Price Target - $5Estimated Time Hold - 2QSupport - $2.75, $3.40Floor - $2.09Double Down Target - Sub $2Option - N/AMicro DD - In March, Akebia submitted an NDA to the FDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. In late May, the FDA accepted for filing the NDA for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis. The FDA assigned the application a standard review and a PDUFA target action date of March 29, 2022. Cash, cash equivalents and available-for-sale securities as of June 30, 2021 were $247.0 million .
4. NDAQ:AKBA | Stock Discussion | Akebia Therapeutics Inc - Stockhouse
Get stock insights, analysis and discussion about Akebia Therapeutics Inc (NDAQ:AKBA). Join the AKBA discussion on Canada's largest online investor ...
Get insights, analysis and discussion about Akebia Therapeutics Inc (NDAQ:AKBA) from Canada’s largest online community of active investors.
5. NASDAQ:AKBA - Akebia Therapeutics, Inc. - TradingView
Bevat niet: conversation | Resultaten tonen met:conversation
View live Akebia Therapeutics, Inc. chart to track its stock's price action. Find market predictions, AKBA financials and market news.
6. Akebia Therapeutics Inc. - AKBA stock - Biotickr
Conversation. 0 following. FOLLOW. Messages Image. Log in or sign up to join the conversation. LoginSign up. 0 Comments on AKBA stock. Newest. AKBA Stock Price.
The biotech company Akebia Therapeutics Inc. trades as AKBA stock on the Nasdaq All Markets. Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD).
7. AKBA Trend - Ainvest
The potential market implications of the FDA approving AKBA's new drug can be analyzed as follows ... Continue this conversation link. iwencai.
The potential market implications of the FDA approving AKBA's new drug can be analyzed as follows:1. Revenue Impact: AKBA's total revenue has shown fluctuations, with the most recent quarter ending on 2023 Q3 indicating a decrease compared to the previous quarter. The FDA approval could positively impact revenue, potentially reversing the recent downward trend.2. EPS and P/E Ratio: The Basic EPS for AKBA has been negative, with slight improvements in recent quarters. The FDA approval could significantly boost EPS, potentially turning it positive. The P/E ratio, currently at -8.91, suggests negative earnings, which might change post-FDA approval.3. Market Sentiment: The market capitalization of AKBA stands at $416.67 million, reflecting investor confidence. Positive news regarding the FDA approval would likely enhance this sentiment, potentially leading to increased investment and a rise in market capitalization.In conclusion, the FDA approval of AKBA's new drug is likely to have positive market implications, impacting revenue, EPS, and market sentiment, potentially reversing recent trends and bolstering investor confidence.${富文本块}
8. AKBA: Akebia Therapeutics Inc - Stock Price, Quote and News - CNBC
Akebia Therapeutics Inc AKBA:NASDAQ · Open1.00 · Day High1.04 · Day Low0.94 · Prev Close0.99 · 52 Week High2.48 · 52 Week High Date03/28/24 · 52 Week Low0.78 · 52 Week ...
Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
9. Foreign Minister Wang Yi Holds Telephone Conversation with His ...
On March 21, 2013, Chinese Foreign Minister Wang Yi exchanged views on bilateral relations with his Iranian counterpart Ali Akba Salehi over the phone.
Foreign Minister Wang Yi Holds Telephone Conversation with His Iranian Counterpart Ali Akba Salehi
10. AKBA - Webull
Bevat niet: conversation | Resultaten tonen met:conversation
The latest AKBA community discussion, real time AKBA market quotes all in the Webull Community.
11. Akebia Therapeutics, Inc. (AKBA) Stock Price, Quote & News
(AKBA). NASDAQ: AKBA · IEX Real-Time Price · USD. Add to Watchlist. 0.989. + ... News. All; Videos; PressPress Releases; Conversation. Akebia Therapeutics to ...
See AlsoKatiana Kay TelegramGet a real-time Akebia Therapeutics, Inc. (AKBA) stock price quote with breaking news, financials, statistics, charts and more.
12. Is Akba going to present good news today-AIME by AInvest
... , these recent announcements and upcoming presentation could potentially have positive implications for the company. Continue this conversation link. iwencai.
There is no specific information indicating that Akebia Therapeutics (AKBA) will present good news today. However, it's important to note that the company recently announced the approval of Vafseo® (vadadustat) in Australia, which could be seen as positive news. Additionally, the company's CEO, John Butler, is scheduled to present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023, which could provide an opportunity for the company to share updates or positive developments.Therefore, while there is no guarantee that the company will present good news today, these recent announcements and upcoming presentation could potentially have positive implications for the company.
13. Akebia Therapeutics (AKBA) Stock Price, News & Info | The Motley Fool
Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis ... Discussion Boards · Calculators · Financial Dictionary. Affiliates & ...
Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis.
14. Akebia Therapeutics Completed Type A Meeting with the FDA and ...
18 jul 2023 · PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...
15. akebia therapeutics inc akba - quote - NYSE
AKEBIA THERAPEUTICS INC AKBA. QUOTE. QUOTE. AKBA. CHART ... Floor Talk with Judy Shaw · Future In Five · LatAm Tech Forum · The Leaderboard.
Please visit this URL to review a list of supported browsers.
16. Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Call Transcript
8 mei 2023 · ... Discussion and Analysis section of our most recent annual and quarterly reports filed with the SEC. The forward-looking statements on this ...
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ETCompany ParticipantsMercedes Carrasco - Senior...
17. AKBA Promotes Axonal Regeneration via RhoA/Rictor to Repair Damaged ...
14 dec 2022 · Discussion. 3.1. Effect of AKBA Intervention on the Bioinformatics of Late SNI. Ubiquitin C-terminal hydrolase L1 (Uchl1) as well as ...
The existing studies by our team demonstrated the pro-recovery effect of 3-Acetyl-11-keto-beta-boswellic acid (AKBA) on a sciatic nerve injury. To further investigate the role of AKBA in peripheral nerve injury repair, The TMT quantitative proteomics technique was used to obtain differentially significant proteins in a Sham group, Model group, and AKBA group. After that, three time points (5, 14, and 28 d) and four groups (Sham + AKBA, Sham, Model, and AKBA) were set up, and immunoblotting, immunofluorescence, and cellular assays were applied to investigate the expression of CDC42, Rac1, RhoA, and Rictor in the sciatic nerve at different time points for each group in more depth. The results showed that AKBA enriched the cellular components of the myelin sheath and axon regeneration after a sciatic nerve injury and that AKBA upregulated CDC42 and Rac1 and downregulated RhoA expression 5 d after a sciatic nerve injury, promoting axon regeneration and improving the repair of a sciatic nerve injury in rats. Rictor is regulated by AKBA and upregulated in PC12 cells after AKBA action. Our findings provide a new basis for AKBA treatment of a peripheral nerve injury.
18. Asahi Kasei Bioprocess America, Inc.'s Post [Video] - LinkedIn
26 jan 2024 · At AKBA, we live and breathe Creativity and Sincerity! Creativity at ... Sincerity in Every Interaction: Transparent communication and ...
At AKBA, we live and breathe Creativity and Sincerity! Creativity at its Core: Innovative ideas flourish in our collaborative environment. Sincerity in…
19. insights into the antimicrobial effects of AKBA against MRSA | AMB Express
6 jan 2024 · ... (AKBA) is a well-studied anti-tumor and antioxidant drug. This study ... Discussion. The increased antibiotic resistance of MRSA and its ...
Staphylococcus aureus is a major threat in infectious diseases due to its varied infection types and increased resistance. S. aureus could form persister cells under certain condition and could also attach on medical apparatus to form biofilms, which exhibited extremely high resistance to antibiotics. 3-Acetyl-11-keto-beta-boswellic acid (AKBA) is a well-studied anti-tumor and antioxidant drug. This study is aimed to determine the antimicrobial effects of AKBA against S. aureus and its persister cells and biofilms. The in vitro antimicrobial susceptibility of AKBA was assessed by micro-dilution assay, disc diffusion assay and time-killing assay. Drug combination between AKBA and conventional antibiotics was detected by checkerboard assay. And the antibiofilm effects of AKBA against S. aureus were explored by crystal violet staining combined with SYTO/PI probes staining. Next, RBC lysis activity and CCK-8 kit were used to determine the cytotoxicity of AKBA. In addition, murine subcutaneous abscess model was used to assess the antimicrobial effects of AKBA in vivo. Our results revealed that AKBA was found to show effective antimicrobial activity against methicillin-resistant S. aureus (MRSA) with the minimal inhibitory concentration of 4–8 µg/mL with undetectable cytotoxicity. And no resistant mutation was induced by AKBA after 20 days of consecutive passage. Further, we found that AKBA could be synergy with gentamycin or amikacin against S. aureus and its c...
20. EktibaFlex® - Unibar
Boswellia has many constituents, but there is one that stands out in its power to help modulate inflammation: AKBA. ... Let's talk ingredients. Connect with ...
High Concentration Boswellic Acid High Concentration Boswellic Acid Highest AKBA Available EktibaFlex® is a highly enriched, extremely bioavailable, and clinically studied extract of the gum resin of the Boswellia serrata tree. It is the first Boswellia extract standardized to contain 90% AKBA (Acetyl-11-keto-beta-bosewella acid), the constituent most responsible for Boswellia’s ability to modulate inflammation.* EktibaFlex® is […]
